[Development and repair of NSAIDs-induced small intestinal lesions: relation to COX isozymes and EP receptor...

Area of Science:

• Gastroenterology
• Pharmacology
• Molecular Biology

Context:

• Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used but associated with gastrointestinal toxicity, particularly intestinal ulceration.
• NSAID-induced intestinal damage involves complex mechanisms including cyclooxygenase (COX) enzyme activity and prostaglandin (PG) production.
• Understanding the roles of COX-1, COX-2, and their downstream products like PGE2 is critical for mitigating NSAID-related side effects.

Purpose:

• To elucidate the intricate roles of COX-1 and COX-2 enzymes and their product, prostaglandin E2 (PGE2), in the pathogenesis and healing of NSAID-induced intestinal ulcers.
• To investigate the specific receptor pathways (EP3/EP4) involved in PGE2-mediated protection and healing.
• To determine the differential involvement of COX isozymes during various stages of intestinal lesion healing.

Summary:

• NSAID-induced intestinal ulceration results from COX-1 and COX-2 inhibition; however, COX-2-derived PGs can counteract COX-1 inhibition's detrimental effects.
• Prostaglandin E2 (PGE2), acting via EP3/EP4 receptors, prevents NSAID-induced lesions by stimulating mucus secretion, inhibiting contractions, reducing bacterial invasion, and down-regulating cytokines.
• PGE2 promotes the healing of these lesions, with COX-2 dominant in early healing and COX-1 in late healing, mediated by EP4 receptor activation and enhanced angiogenesis via VEGF.

Impact:

• This research deepens the understanding of NSAID enteropathy mechanisms, identifying key molecular targets for therapeutic intervention.
• Findings highlight the potential of targeting PGE2 pathways for developing novel gastroprotective agents against NSAID-induced intestinal damage.
• The study provides insights into the differential roles of COX isozymes in tissue repair, relevant for managing inflammatory conditions and promoting healing.